Introduction
Renal cell carcinoma (RCC) is the most common malignancy of human kidney and accounts for approximately 2% of adult malignancies. It is estimated that the world-wide incidence of RCC. The Von Hippel-Lindau (VHL) gene alterations are responsible for a rare hereditary cancer syndrome, including inherited RCC. The VHL gene and its importance in regulation of the hypoxia pathway through the hypoxia inducible factors (HIFs), the VHL disease is an uncommon autosomal dominant disorder with high penetrance, which predisposes to a variety of neoplastic and non-neoplastic lesions affecting the multiple organs. The disease is caused by mutation of the VHL tumor suppressor gene (VHL gene) on the short arm of chromosome 3 (3p25-26) the gene spans 10 kb, is composed of three exons [ Figure 1 ] and encodes two proteins (pVHL19 and pVHL30). The complete VHL protein consists of 214 amino acids and has two structural domains: The α-domain and the β-domain. [1] Regulation of the expression of HIF-alpha (HIF-α) by the pVHL/E3 ubiquitin ligase complex is critical for the normal functioning of a cell. HIF is a heterodimeric transcription factor that mediates the cell's response to hypoxia. HIF is composed of a α-subunit (HIF-α), which is oxygen-sensitive and a β-subunit (HIF-1 β), which is constitutively expressed. In normoxia, key proline residues within HIF-α are prolyl hydroxylated.
This enables recognition of HIF-α by the pVHL/E3
ubiquitin ligase complex and leads to polyubiquitination and degradation of HIF-α. In hypoxia due to the lack of available oxygen, hydroxylation of the proline residues does not occur and pVHL does not recognize HIF-α.
The HIF-α protein then translocates to the nucleus where it dimerizes with HIF-1 β and activates the transcription of target genes. [2, 3] However, if loss of functional pVHL occurs due to the genetic or epigenetic events in normoxia, HIF-α is not targeted for degradation Von Hippel-Lindau (VHL) disease is an autosomal dominant hereditary cancer syndrome that predisposes to the development of a variety of benign and malignant tumors, especially cerebellar hemangioblastomas, retinal angiomas and clear-cell renal cell carcinomas (RCC). We have identified of VHL gene using immunohistochemistry in a patient who was diagnosed for RCC. In order to understand the involvement of mutation in the VHL gene exon 1 was amplified and sequenced (accession number: JX 401534).
The sequence analysis revealed the presence of novel missense mutations c.194 C>T, c.239 G>A, c.278 G>A, c.319 C>G, c. 337 C > G leading to the following variations and consequently is constitutively up-regulated. This is a frequent occurrence in RCC. [4] The basic biology underlying the development of clear cell renal cell carcinoma is critically dependent on the VHL gene, whose protein product is important in the cell's normal response to hypoxia. Aberrations in VHL's function, either through mutation or promoter hypermethylation, lead to accumulation of the transcriptional regulatory molecule, HIF-α. [5, 6] In view of the importance of VHL gene in such conditions the present study is aimed to characterize VHL in an Indian patient reported in Sri Venkateswara residue to glutamic acid (p.Gly 93 Glu), respectively. Therefore, these missense mutations observed in the patient confirms the involvement of VHL gene mutation in the RCC condition.
Discussion
The VHL gene has been found to have the characteristics of a tumor suppressor gene. In clear cell renal carcinoma patient's high percentage of tumors is associated with one inherited allele of the VHL gene, targets such as vascular endothelial growth factor, glucose transporter 1, platelet-derived growth factor and transforming growth factor α resulting in RCC. [7] Point mutations occur in about 60% of cases and large deletions in about 40%. VHL 1 (without pheochromocytoma) is mainly produced by mutations Table 1 and Figure 3b -f]. [8] Studies showed that VHL gene mutations results in inactivation of this gene, which is observed major conventional RCCs. [9] Chromosome 3 (3p25-26) deletions may act as risk factors for clear cell renal carcinoma development in VHL families and they should be investigated for VHL mutations by molecular genetic testing. Pre-symptomatic detection of the affected gene facilitates early diagnosis and improved prognosis.
